Jingjing Wang
83 Fen Yang Road
Shanghai, 200031, China
Shanghai, 200031, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Pharmacokinetics of Aztreonam-Avibactam After Single- and Multiple-Dose Administration: A Phase 1, Open-Label Study in Healthy Chinese Participants and Ethnic Comparison with Non-Chinese Participants.
Journal: Clinical pharmacology in drug development
Published: August 14, 2025
Safety, pharmacokinetics, and pharmacodynamics of GS1-144, a neurokinin-3 receptor antagonist: A randomized phase 1 single and multiple ascending dose and food effect study.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: July 15, 2025
Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study.
Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study.
Journal: Advances in therapy
Published: May 17, 2024
Pharmacokinetics and safety of colistin sulfate after single and multiple intravenous doses in healthy Chinese subjects.
Journal: International journal of antimicrobial agents
Published: March 19, 2024
A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects.
Journal: Antimicrobial agents and chemotherapy
Published: October 30, 2023
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study.
Journal: Expert opinion on investigational drugs
Published: June 26, 2023
Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis.
Journal: The British journal of dermatology
Published: February 07, 2023
Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis.
Journal: Frontiers in pharmacology
Published: December 31, 2022
LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects.
Journal: Frontiers in pharmacology
Published: November 30, 2022
Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling.
Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University
Published: February 11, 2022
Last Updated: 09/26/2026